HB 1074 would create a new North Carolina individual income tax deduction for certain prescription drug expenses. Specifically, it allows taxpayers to deduct up to $5,000 of unreimbursed out-of-pocket costs for prescribed medications and pharmacy cost-sharing when those expenses are included in adjusted gross income. The deduction cannot be claimed for amounts already paid through tax-favored accounts such as a Flexible Spending Account or Health Savings Account, and it cannot be duplicated with another existing deduction for the same expenses in the same tax year.
The bill amends G.S. 105-153.5, which governs modifications to adjusted gross income for North Carolina taxable income. Its practical effect would be to reduce taxable income for eligible taxpayers beginning with tax years starting on or after January 1, 2026, potentially lowering state income tax liability for people with significant prescription drug costs. The bill is framed as a targeted tax relief measure for individuals facing high medication and pharmacy cost-sharing expenses.
HB 1074 would change North Carolina’s income tax code by adding a new itemized-style deduction within the state’s AGI modifications for unreimbursed prescription drug and pharmacy cost-sharing expenses. It would affect individual taxpayers who pay out of pocket for prescribed medications, while excluding expenses already covered by FSAs, HSAs, or another overlapping deduction. The bill would not directly regulate drug pricing or insurance coverage, but it would reduce taxable income for qualifying taxpayers and could modestly lower state revenue beginning in tax year 2026.
Based on the bill text and available legislative history, the measure appears to be presented as a consumer tax relief proposal with no recorded committee debate or roll-call votes in the provided materials. The sponsorship and framing suggest generally favorable intent toward helping residents manage prescription costs. The bill’s referral to Health, Finance, and Rules indicates it is being processed through the normal committee path, but no explicit opposition or support statements are available in the record provided.
The main policy questions likely concern the fiscal cost of the deduction, whether the $5,000 cap is appropriately targeted, and whether the benefit should be limited to unreimbursed expenses only. Another possible point of contention is overlap with existing tax deductions and tax-favored accounts, since the bill expressly prevents double benefits. Any disagreement would likely center on whether state tax relief is the best way to address prescription affordability, versus broader health care or pharmaceutical policy changes.